Allergan, Inc. (NYSE:AGN) announced the U.S. Food and Drug Administration's (FDA) approval of JUVEDERM(R) XC, a new formulation of the currently FDA-approved JUVEDERM(R) dermal filler and the latest advancement1 in hyaluronic acid (HA) dermal fillers. Allergan's new JUVEDERM(R) formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds (or "parentheses") that appear around the nose and mouth. JUVEDERM(R) is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment2 and number-one selling hyaluronic acid dermal filler.3 "As the global leader in medical aesthetics, Allergan is committed to providing the latest scientific advancements in facial aesthetic products to meet patients' demands and further optimize their experiences, " said Robert Grant, Allergan's Corporate Vice President and President, Allergan Medical.
AcademyHealth recognized research that improves patient safety and surgical outcomes with the 2010 Health Services Research (HSR) Impact Award. The WHO Surgical Safety Checklist was created as a tool to ensure adherence to basic safety standards of care. "With this award AcademyHealth recognizes research that clearly translated into policy and, ultimately, made our health care system better, " said AcademyHealth President W. David Helms, Ph.D. "The WHO Surgical Safety Checklist exemplifies how health services research can inform the decision making process and ultimately impact the lives of Americans in a positive and beneficial manner." In 2006 the World Health Organization asked Dr. Atul Gawande to develop an approach to reduce surgical harm globally. Over the next two years, Dr. Gawande led a team of international experts from surgery, anesthesiology, and nursing in defining a core set of safety standards that can be applied to high and low income countries alike. In its initial multi-city, multinational study, the 19-item checklist developed by Dr.
Grant C. Jaquith, Temporary Acting United States Attorney for the Northern District of New York, and Mark Dragonetti, Special Agent-in-Charge of the Food and Drug Administration, Office of Criminal Investigations, New York Field Office, announced that The Plastic Surgery Group, LLP (TPSG) of Albany, New York, was sentenced and ordered to pay restitution in the amount of $106, 686, and a fine of $200, 000, in connection with TPSG's plea of guilty to one felony count of misbranding drugs, in violation of Title 21, United States Code, Sections 331(k), 352(i)(3), and 333(a)(2). TPSG was sentenced in Federal District Court in Albany, New York by District Judge Thomas J. McAvoy. Additionally, Doctors William F. De Luca, Jr., Douglas M. Hargrave, Jeffrey L. Rockmore, Steven M. Lynch, And John D. Noonan, were sentenced to probation with community service, and ordered to pay restitution in the amount of $106, 686, and a fine of $5, 000. TPSG's practice administrator, Peter M.
The economic situation does not appear to have affected the cosmetic surgery business in Britain: new figures from a not-for-profit organisation show that the number of surgical procedures were 6.7 per cent higher in 2009 than 2008, among which the number of male breast reductions went up by 80 per cent. These figures, released on 1st February, are from the latest audit by the British Association of Aesthetic Plastic Surgeons (BAAPS), a not-for-profit organisation that describes its purpose as being to advance the education and practice of Aesthetic Plastic Surgery for public benefit. Despite the recession, said the BAAPS in a press statement, 36, 482 surgical procedures took place in Britain last year, up from 34, 187 in 2008. The audit also highlighted that: In women, procedures went up from 31, 183 in 2008 to 32, 859 in 2009 (just over 5 per cent increase). In men, procedures went up from 3, 004 in 2008 to 3, 623 in 2009 (21 per cent increase). In men, the number of breast reduction or or gynaecomastia operations (to remove "man boobs") went up from 323 in 2008 to 581 in 2009 (80 per cent increase).
Bariatric weight-loss surgery may sound dangerous and complicated, but a Geisinger physician warns that the real danger may be a life of obesity. "There are risks associated with bariatric surgery, as there are with any surgical procedure, but the risks associated with the procedure may pale in comparison to the health complications that can be caused by obesity, " said Christopher Still, D.O., director of the Geisinger Center for Nutrition and Weight Management. Bariatric surgery is a weight-loss procedure that can help obese individuals significantly reduce their body weight and can improve a patient's overall health. Obesity can lead to a variety of complications including sleep apnea, diabetes, fatty liver disease, and heart disease, all of which require medical attention, Dr. Still said, and patients who may be considering bariatric surgery are often burdened by one or more of these conditions. "Some obesity-related conditions can be fatal, and others require chronic medication and treatment, " Dr.
The Plastic Surgery Center today announced that an innovative nerve graft transplant performed by Dr. Andrew Elkwood has proven to be successful in treating and preventing posterior pressure ulcers - one of the leading causes of mortality among paraplegics. 49-year old Tory Cavalieri, who underwent the procedure last January, has regained sensation in his posterior and is free of acute pressure sores, which had left him bedridden for years. "We are absolutely thrilled with Tory's results and the incredible implications for the wheelchair-bound community at large, " said Dr. Elkwood. "The success of this procedure can prove to be life-changing for tens of thousands of people worldwide whose lives are subjugated by acute posterior sores." The nerve graft, which was performed by Dr. Elkwood in January 2009, was intended to restore sensation to the posterior of Mr. Cavalieri, who suffered from acute pressure sores. As part of the two-hour procedure, Dr. Elkwood and his team removed 12 inches of functioning sural nerve from Mr.
BioTime, Inc. (NYSE Amex:BTIM) reported recently-released results from an independent study evaluating the use of Hextend® in hemodynamically unstable trauma patients. Hextend (6% Hetastarch in Lactated Electrolyte Injection) is BioTime's commercially-available blood plasma volume expander used to treat hypovolemia (low blood volume). The study, conducted at the University of Miami Ryder Trauma Center, reported that initial resuscitation with Hextend was associated with no obvious coagulopathy and reduced mortality compared to fluid resuscitation without Hextend. The non-randomized observational trial was the largest involving Hextend in any group of surgical patients and was conducted by a team of physicians led by Kenneth G. Proctor, Ph.D. at the University of Miami Ryder Trauma Center, a Level 1 trauma center, from June 2008 through December 2008. The results were presented at the prestigious Southern Surgical Association 2009 Annual Meeting in December by Drs. Alan S. Livingstone, chair of Miami's Department of Surgery, and Michael P.
Palomar Medical Technologies, Inc. is pleased to announce that the Lux1540™ Fractional non-ablative laser handpiece has received the first clearance by the United States Food and Drug Administration (FDA) for the treatment of striae (stretch marks) using a fractional laser. This new clearance will allow aesthetic practitioners to treat the millions of women worldwide who have unwanted stretch marks. Ongoing clinical studies have shown that subjects treated with the Lux1540 achieved an average improvement of between 51% and 75% in the appearance of their striae, based upon a blinded review of photographs comparing the pre-treatment appearance of striae versus the results three months post-treatment. Francesca de Angelis, MD, a leading plastic surgeon from Naples, Italy who has led the research effort, noted, "Through our ongoing clinical study, and with thousands of satisfied patients treated throughout Italy, we have found that the Lux1540 is the first laser treatment for stretch marks that truly works.
Suneva Medical, a privately-held aesthetic medical device company, announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients. The studies were presented at the Advances in Cosmetic and Medical Dermatology's "Maui Derm 2010" Meeting in Maui, Hawaii January 23-27th and the American Academy of Cosmetic Dermatology (AACS) Scientific Meeting in Orlando, Florida January 28-31st. A retrospective review of 11 patients was presented by Joseph A. Eviatar, M.D., FACS, Chelsea Eye and Cosmetic Surgery Associates, New York Medical College, at the AACS Scientific Meeting. The study evaluated the safety and efficacy of pan facial soft tissue augmentation with Artefill for the correction of lipoatrophy in HIV patients. Three patients were previously treated with Sculptra, six with Radiesse. Patients received Artefill injections over a six-month period until full correction was achieved. Changes were evaluated from baseline using a 0 to 4 atrophic grading scale.
Shark attack! These words can send waves of fear through the public and often guarantee prominent coverage in the news media - even if the bite is little more than a scratch. To better communicate the actual severity of the bite, University of Florida researchers have created a grading scale, similar to how burn severity is ranked by degrees. The new scale is detailed in this month's The American Surgeon. UF researchers reviewed the 96 cases containing complete medical records from more than 4, 000 entries in the International Shark Attack File, a record maintained by UF's Florida Museum of Natural History. Assigning scores to clinical findings such as blood pressure, location and depth of injury, damage to organs, and death, the team created a scoring system called the Shark-Induced Trauma Scale, or SIT Scale. Lead researcher Ashley Lentz, M.D., a plastic and reconstructive surgery fellow at the UF College of Medicine, said compiling the total score using the SIT assessment indicates the level of bite severity as outlined in the newly created five-level grading system.